[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339486-105":59,"doc-detail-339486-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-ovarex-study-establishment-of-ex-vivo-ovarian-cancer-models-to-validate-innovative-therapies-and-to-identify-predictive-biomarkers","The OVAREX study - Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers","","Ovarian cancer remains a leading cause of death in gynecological malignancies, largely driven by development of chemoresistance and persistently modest 5-year overall survival despite PARP inhibitors. The OVAREX study develops and evaluates functional assays using patient-derived tumor models to test feasibility of in vivo and ex vivo systems and to improve treatment selection. Ex vivo models include PDTO, ADS, and explants, with molecular and histological characterization to compare origin and paired responses for predictive biomarker discovery.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-ovarex-study-establishment-of-ex-vivo-ovarian-cancer-models-to-validate-innovative-therapies-and-to-identify-predictive-biomarkers/339486/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-ovarex-study-establishment-of-ex-vivo-ovarian-cancer-models-to-validate-innovative-therapies-and-to-identify-predictive-biomarkers/339486.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the OVAREX study address in ovarian cancer treatment?","Question",{"text":112,"@type":113},"The study targets ovarian cancer mortality driven by chemoresistance and the need for better therapeutic strategies. It focuses on identifying predictive biomarkers and anticipating responses to treatments.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What ex vivo and in vivo models does the OVAREX study use?",{"text":117,"@type":113},"Patient-derived xenografts (PDX) are generated from tumor fragments engrafted into immunocompromised mice. Ex vivo models are created as explants, ascites-derived spheroids (ADS), and patient-derived tumor organoids (PDTO) from tumor tissues or ADS.",{"name":119,"@type":110,"acceptedAnswer":120},"How will the study evaluate the predictive value of the models?",{"text":121,"@type":113},"Responses of ex vivo tumor-derived models to conventional chemotherapy and PARP inhibitors will be assessed and compared with companion diagnostic test results and patients’ clinical responses. Molecular and histological characterizations will also be performed to compare tumors of origin with paired models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339486,1790605769,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Thorel et al. BMC Cancer (2024) 24:701 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12429-w](https://doi.org/10.1186/s12885-024-12429-w)  \nSTUDY PROTOCOL Open Access  \nThe OVAREX study: Establishment of ex vivo  ovarian cancer models to validate innovative therapies and to identify predictive  \nbiomarkers  \nLucie Thorel 1,2, Jordane Divoux 1,2,3, Justine Lequesne4, Guillaume Babin 1,5, Pierre-Marie Morice 1,2, Romane Florent 1,2,3, Guillaume Desmartin2,3, Lucie Lecouflet2,3, Chloé Marde Alagama 1, Alexandra Leconte4, Bénédicte Clarisse4, Mélanie Briand 1,6, Roman Rouzier5, Léopold Gaichies5, Sandrine Martin-Françoise5, Jean-François Le Brun5, Christophe Denoyelle 1,2, Nicolas Vigneron 1,2,7, Corinne Jeanne8, Cécile Blanc-Fournier 1,6,8, Raphaël Leman9, Dominique Vaur9, Martin Figeac 10, Matthieu Meryet-Figuiere 1,2, Florence Joly4, Louis-Bastien Weiswald 1,2,3*, Laurent Poulain 1,3,6*† and Enora Dolivet 1,5*†  \nAbstract  \nBackground Ovarian cancer is the first cause of death from gynecological malignancies mainly due to development of chemoresistance. Despite the emergence of PARP inhibitors, which have revolutionized the therapeutic management of some of these ovarian cancers, the 5-year overall survival rate remains around 45% . Therefore, it is crucial to develop new therapeutic strategies, to identify predictive biomarkers and to predict the response to treatments. In this context, functional assays based on patient-derived tumor models could constitute helpful and relevant tools for identifying efficient therapies or to guide clinical decision making.  \nMethod The OVAREX study is a single-center non-interventional study which aims at investigating the feasibility of establishing in vivo and ex vivo models and testing ex vivo models to predict clinical response of ovarian cancer patients. Patient-Derived Xenografts (PDX) will be established from tumor fragments engrafted subcutaneously into immunocompromised mice. Explants will be generated by slicing tumor tissues and Ascites-Derived Spheroids (ADS) will be isolated following filtration of ascites. Patient-derived tumor organoids (PDTO) will be established after dissociation of tumor tissues or ADS, cell embedding into extracellular matrix and culture in specific medium. Molecular and histological characterizations will be performed to compare tumor of origin and paired models.  \n†Laurent Poulain and Enora Dolivet contributed equally to this work.  \n*Correspondence:  \nLouis-Bastien Weiswald [lb.weiswald@baclesse.unicancer.fr](lb.weiswald@baclesse.unicancer.fr)[ ](lb.weiswald@baclesse.unicancer.fr)Laurent Poulain [l.poulain@baclesse.unicancer.fr](l.poulain@baclesse.unicancer.fr)[ ](l.poulain@baclesse.unicancer.fr)Enora Dolivet[e.dolivet@baclesse.unicancer.fr](e.dolivet@baclesse.unicancer.fr)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless oth","cbCain0goZSyNmJY","https://ap.wps.com/l/cbCain0goZSyNmJY","pdf",2244426,"English","# Abstract\n## Background\n## Method\n## Discussion\n## Trial registration\n## Keywords\n# Background\n## Ovarian cancer: epidemiology and therapeutic management","[{\"question\":\"What problem does the OVAREX study address in ovarian cancer treatment?\",\"answer\":\"The study targets ovarian cancer mortality driven by chemoresistance and the need for better therapeutic strategies. It focuses on identifying predictive biomarkers and anticipating responses to treatments.\"},{\"question\":\"What ex vivo and in vivo models does the OVAREX study use?\",\"answer\":\"Patient-derived xenografts (PDX) are generated from tumor fragments engrafted into immunocompromised mice. Ex vivo models are created as explants, ascites-derived spheroids (ADS), and patient-derived tumor organoids (PDTO) from tumor tissues or ADS.\"},{\"question\":\"How will the study evaluate the predictive value of the models?\",\"answer\":\"Responses of ex vivo tumor-derived models to conventional chemotherapy and PARP inhibitors will be assessed and compared with companion diagnostic test results and patients’ clinical responses. Molecular and histological characterizations will also be performed to compare tumors of origin with paired models.\"}]","The OVAREX study - Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers | PDF",1790030536,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1d1ad249665547a6c65de834b39cf0e.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33b07f48f3499f00e2857bb0e380fd3d.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ebbea392a3f6f1ca63f0b919b363de6.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5bfa82236d7bf542b7eafa6e5213290.webp",980,1306]